Literature DB >> 23594179

Limitations to the identification of HIV-associated neurocognitive disorders in clinical practice.

D Morley1, P McNamara, S Kennelly, G McMahon, C Bergin.   

Abstract

OBJECTIVES: The objective of this study was to establish the level of awareness of HAND among healthcare providers, the screening tools that are currently used in its detection and factors that limit cognitive assessments.
METHODS: We distributed a 12-item questionnaire to doctors and nurses who work in the Department of Genitourinary Medicine and Infectious Disease (GUIDE) service and also to doctors who work in the emergency department (ED) at St James Hospital.
RESULTS: 35 surveys were collected, 54% (n = 19) from the GUIDE service and 46% (n = 16) from the ED. 82% (n = 29) of participants were doctors from interns to consultants. There was reasonable appreciation among participants with regards the prevalence of neurocognitive impairment (estimated at 29.1% among patients on HAART, and 39.3% among patients not on HAART). Screening tools were rarely used by GUIDE and ED clinicians (25% vs. 15% of the time). The Mini Mental State Examination (MMSE) was previously used by 37% (n = 13) of the group. Very few people had used the HIV Dementia Scale (HIVDS) 6% (n = 2). 34% of respondents felt that 'Orientation in Person, Place and Time was a sufficient screening tool for cognitive assessment'. Lack of time, exposed environment and lack of availability of screening tool were cited as limitations to cognitive screening in the ED environment.
CONCLUSIONS: This study examines awareness of HAND among healthcare providers and also reasons for inadequate assessment. There is a need for consensus on screening guidelines. A quick, easy to use and readily available screening tool may have a role in the acute setting in identifying high-risk patients.
© 2013 British HIV Association.

Entities:  

Keywords:  HIV; neurocognitive impairment; survey study

Mesh:

Year:  2013        PMID: 23594179     DOI: 10.1111/hiv.12036

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  4 in total

1.  Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits.

Authors:  Linda Chang; Caroline Jiang; Eric Cunningham; Steven Buchthal; Vanessa Douet; Marilou Andres; Thomas Ernst
Journal:  Neurology       Date:  2014-05-21       Impact factor: 9.910

Review 2.  Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity.

Authors:  Reuben N Robbins; Travis M Scott; Hetta Gouse; Thomas D Marcotte; Sean B Rourke
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 3.  Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.

Authors:  Howard E Gendelman; Harris A Gelbard
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

4.  CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders.

Authors:  Dionna W Williams; Desiree Byrd; Leah H Rubin; Kathryn Anastos; Susan Morgello; Joan W Berman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.